Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Second-Line Therapy Options: Role of Trabectedin

November 14th 2017

Soft Tissue Sarcoma: Decisions Following Progression

November 14th 2017

Changing Treatment Landscape in Soft Tissue Sarcoma

November 14th 2017

Olaratumab's Role in Soft Tissue Sarcoma

November 14th 2017

Soft Tissue Sarcoma: Selecting Among Frontline Options

November 14th 2017

First-line Options in Soft Tissue Sarcoma

November 14th 2017

Initial Treatment Approach in Soft Tissue Sarcoma

November 14th 2017

Common Pitfalls With Treating Soft Tissue Sarcoma

November 14th 2017

Collaboration of Experts in Soft Tissue Sarcoma

November 14th 2017

Ongoing Management Decisions in Soft Tissue Sarcoma

November 14th 2017

Multidisciplinary Team in Soft Tissue Sarcoma

November 14th 2017

How Sarcoma Experts Work With Community Oncologists

November 14th 2017

Histopathological Diagnosis in Soft Tissue Sarcoma

November 14th 2017

Heterogeneity of Soft Tissue Sarcomas

November 14th 2017

Pazopanib Regimen Active, But Misses Mark in Leiomyosarcoma

September 12th 2017

Although second-line treatment with combined pazopanib and gemcitabine demonstrated disease control in the majority of patients with metastatic or relapsed uterine or soft tissue leiomyosarcomas, the phase II UNICANCER SARCOME 11 study did not meet statistical endpoints and is considered a negative trial.

Expert Discusses CMB305 Immunotherapy Regimen in Sarcoma

August 7th 2017

Neeta Somaiah, MD, discusses the efficacy of CMB305 in patients with synovial sarcoma or myxoid/round cell liposarcoma.

Dr. Somaiah on Next Steps for CMB305 in Soft Tissue Sarcoma

August 3rd 2017

Neeta Somaiah, MD, assistant professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the next steps following the phase I findings of the CMB305 trial in patients with NY-ESO-1–positive recurrent soft tissue sarcoma.

10-Year Trabectedin Real-World Data Demonstrate Efficacy in Sarcoma

July 26th 2017

Long-term follow-up showed that trabectedin (Yondelis) was associated with high rates of survival and clinical benefit rate for patients with advanced high grade soft tissue sarcomas.

Cediranib Reduces Tumor Burden in Sarcoma

July 21st 2017

Cediranib was associated with significantly reduced tumor burden and superior progression-free survival compared with placebo in patients with alveolar soft part sarcoma.

Radiation Therapy, Chemotherapy, Targeted Therapy, and Possibly Immunotherapy in Localized Sarcoma

July 19th 2017

As clinicians have gained an improved understanding of the biology of soft-tissue sarcoma malignancies, the ability to better distinguish and identify subtypes has extended the hope of targeted treatment options.